trafficking protein particle complex subunit 2LGenealiases: HSPC176 · PERRB
Q-omics provides the consensus-scored TRAPPC2L profile across patient tissues and cancer cell-line models. TRAPPC2L expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TRAPPC2L is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TRAPPC2L protein abundance shows 17,164 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, KIRC, and LSCC as cancer lineages where TRAPPC2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAPPC2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAPPC2L survival associations across molecular data types. TRAPPC2L RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAPPC2L RNA expression–survival associations across cancer types. High TRAPPC2L expression shows unfavorable associations in LIHC and ACC, but favorable associations in UCEC, MESO, OV and SCLC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for TRAPPC2L RNA expression.
This table summarizes TRAPPC2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRAPPC2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAPPC2L shows higher tumor expression in KIRC, COAD, HNSC, LIHC, KIRP and CHOL. The KIRC box plot shows higher TRAPPC2L RNA expression in tumor versus normal tissue (log2 FC = +0.939, t-test p < 0.001).
This table shows molecular features associated with TRAPPC2L in patient tissues and cancer cell lines. In patient samples, TRAPPC2L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRAPPC2L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
